We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-18.65%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$626M
AUM Growth
-$126M
Cap. Flow
+$63M
Cap. Flow %
10.07%
Top 10 Hldgs %
43.21%
Holding
89
New
9
Increased
11
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
OMER icon
Omeros
OMER
+$24.5M
2
SAGE
Sage Therapeutics
SAGE
+$14.8M
3
RMTI icon
Rockwell Medical
RMTI
+$10.1M
4
ZYNE
Zynerba Pharmaceuticals, Inc
ZYNE
+$8.75M
5
HRTX icon
Heron Therapeutics
HRTX
+$8.19M

Top Sells

Rank Stock Value
1
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$41.8M
2
KERX
Keryx Biopharmaceuticals Inc
KERX
+$8.24M
3
NGNE icon
Neurogene
NGNE
+$1.5M
4
FOLD
Amicus Therapeutics
FOLD
+$784K
5
NSTG
NanoString Technologies, Inc.
NSTG
+$627K

Sector Composition

Rank Sector Weight
1 Healthcare 80.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRTX icon
1
Heron Therapeutics
HRTX
$94.1M
$41.1M 6.57%
1,685,719
+245,719
+17% +$8.19M
ALKS icon
2
Alkermes
ALKS
$8.39B
$41.1M 6.56%
700,000
– –
NBIX icon
3
Neurocrine Biosciences
NBIX
$18.7B
$28.6M 4.57%
718,900
– –
DYAX
4
DELISTED
DYAX CORPORATION
DYAX
$26.7M 4.27%
1,400,000
– –
ARDX icon
5
Ardelyx
ARDX
$1.25B
$25.6M 4.09%
1,481,075
– –
ALDR
6
DELISTED
Alder Biopharmaceuticals
ALDR
$24.8M 3.96%
757,475
– –
EGRX
7
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$22.2M 3.55%
300,000
– –
OMER icon
8
Omeros
OMER
$863M
$21.5M 3.43%
1,960,000
+1,571,500
+405% +$24.5M
PTLA
9
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$21.3M 3.4%
500,000
– –
SRNE
10
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$17.6M 2.81%
2,095,334
+150,000
+8% +$2.39M
QTNT
11
DELISTED
Quotient Limited Ordinary Shares
QTNT
$14.5M 2.32%
27,978
– –
DVAX
12
DELISTED
Dynavax Technologies
DVAX
$14.1M 2.25%
575,000
+75,000
+15% +$2.12M
DXCM icon
13
DexCom
DXCM
$28.8B
$13.1M 2.1%
612,000
– –
BCRX icon
14
BioCryst Pharmaceuticals
BCRX
$2.35B
$12.3M 1.97%
1,080,000
+400,000
+59% +$5.34M
NVRO
15
DELISTED
NEVRO CORP.
NVRO
$12.3M 1.97%
265,386
+56,886
+27% +$2.76M
TSRO
16
DELISTED
TESARO, Inc.
TSRO
$11.7M 1.87%
291,250
– –
CHRS icon
17
Coherus Oncology
CHRS
$227M
$11.4M 1.82%
569,130
– –
NVAX icon
18
Novavax
NVAX
$1.22B
$11.3M 1.81%
80,000
– –
ALNY icon
19
Alnylam Pharmaceuticals
ALNY
$27.4B
$11.3M 1.8%
140,000
– –
RARE icon
20
Ultragenyx Pharmaceutical
RARE
$2.56B
$10.5M 1.68%
109,500
+7,500
+7% +$859K
SAGE
21
DELISTED
Sage Therapeutics
SAGE
$10.2M 1.62%
+240,000
New +$14.8M
CBPO
22
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$10M 1.6%
111,500
– –
COLL icon
23
Collegium Pharmaceutical
COLL
$1.17B
$9.95M 1.59%
450,000
– –
SCTL
24
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$9.38M 1.5%
869,700
– –
PFNX
25
DELISTED
Pfenex Inc.
PFNX
$9.38M 1.5%
624,900
– –
1
2 3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q3 2015 Portfolio in Review

As of Q3 2015, Cormorant Asset Management held 89 positions worth $626M, down 17% from $752M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Cormorant Asset Management deployed $63M of net new capital in Q3 2015, opening 9 new positions and adding to 11 existing holdings. Its largest new stake was Sage Therapeutics: 240,000 shares worth $10.2M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 74% a quarter earlier.

On the sell side, the largest reduction was Neurogene, an estimated $1.5M trimmed.

  • Cormorant Asset Management's largest Q3 2015 buy was Sage Therapeutics: 240,000 shares worth $10.2M.
  • Cormorant Asset Management added most to Omeros in Q3 2015, an estimated $24.5M increase.
  • Cormorant Asset Management's biggest Q3 2015 reduction was Neurogene, cutting an estimated $1.5M.
  • Cormorant Asset Management fully exited RECEPTOS INC COM STK (DE) in Q3 2015, selling an estimated $41.8M.
  • Cormorant Asset Management's ten largest holdings make up 43% of its $626M portfolio in Q3 2015.
  • Cormorant Asset Management opened 9 new positions and closed 2 in Q3 2015.
  • Cormorant Asset Management's portfolio value fell 17% quarter-over-quarter to $626M.

Based on Cormorant Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.